FDA issues Guidance for a clear Identification of pharmaceutical Companies
Recommendation
21-23 May 2025
Copenhagen, Denmark
Initial and Continuous Professional Training for GMP Auditors
In our GMP News from September 2013 you learned about a draft of a FDA Guidance for Industry entitled "Specification of the Unique Facility Identifier (UFI) System for Drug Establishment Registration". This document's goal was to clearly identify pharmaceutical sites. The draft comprised (manageable) five pages - including the cover page. And in terms of volume this didn't change. However, some of the alternatives still mentioned in the draft, are not stated any longer - as one can find out when contacting the authority in these cases. The method now wanted is a registration by a D-U-N-S- (Data Universal Numbering System) number. This number - which is a 9-digit code - is supplied by the company Dun & Bradstreet.
To find out more please see the complete Guidance for Industry "Specification of the Unique Facility Identifier (UFI) System for Drug Establishment Registration".
Related GMP News
02.10.2024MHRA: New Rules for Manufacturers and Wholesalers after Brexit
24.09.2024What is RCA (Root Cause Analysis)?
18.09.2024Lack of GMP Training and related Documentation: What Deviations can be found in FDA Warning Letters?
04.09.2024Switzerland: Changes for the Qualification of QPs (Responsible Person; RP in Switzerland)
04.09.2024Insufficient Root Cause Analysis leads to FDA Warning Letter
28.08.2024Switzerland to implement Measures to combat Shortages of Medicines